Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

Show full item record



Permalink

http://hdl.handle.net/10138/203755

Citation

Pokorney , S D , Piccini , J P , Stevens , S R , Patel , M R , Pieper , K S , Halperin , J L , Breithardt , G , Singer , D E , Hankey , G J , Hacke , W , Becker , R C , Berkowitz , S D , Nessel , C C , Mahaffey , K W , Fox , K A A , Califf , R M , ROCKET AF Steering Comm & Kaste , M 2016 , ' Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF ' , Journal of the American Heart Association , vol. 5 , no. 3 , 002197 . https://doi.org/10.1161/JAHA.115.002197

Title: Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF
Author: Pokorney, Sean D.; Piccini, Jonathan P.; Stevens, Susanna R.; Patel, Manesh R.; Pieper, Karen S.; Halperin, Jonathan L.; Breithardt, Gunter; Singer, Daniel E.; Hankey, Graeme J.; Hacke, Werner; Becker, Richard C.; Berkowitz, Scott D.; Nessel, Christopher C.; Mahaffey, Kenneth W.; Fox, Keith A. A.; Califf, Robert M.; ROCKET AF Steering Comm; Kaste, Markku
Contributor: University of Helsinki, Neurologian yksikkö
Date: 2016-03
Language: eng
Number of pages: 13
Belongs to series: Journal of the American Heart Association
ISSN: 2047-9980
URI: http://hdl.handle.net/10138/203755
Abstract: Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereas
Subject: atrial fibrillation
mortality
rivaroxaban
stroke
warfarin
CONGESTIVE-HEART-FAILURE
CATHETER ABLATION
RISK-FACTOR
FOLLOW-UP
WARFARIN
THERAPY
DABIGATRAN
STROKE
METAANALYSIS
EFFICACY
3124 Neurology and psychiatry
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
e002197.full.pdf 1.716Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record